<DOC>
	<DOCNO>NCT00718419</DOCNO>
	<brief_summary>To determine whether study single-agent enzastaurin warrant patient previously treat Waldenstrom 's Macroglobulinemia Multiple Myeloma base response .</brief_summary>
	<brief_title>A Study Patients That Have Been Previously Been Treated Waldenstrom 's Macroglobulinemia Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>At least 18 year age . Patients must WM MM previously treat least 1 5 prior therapy . Treatment prior autologous transplant permit . If transplant use consolidation follow chemotherapy , without intervene disease progression , consider 1 line treatment precede chemotherapy . Patients MM must monoclonal protein serum great equal 1 g/dL monoclonal light chain urine protein electrophoresis great equal 200 mg/ 24 hour , measurable plasmacytoma . Patients WM must immunoglobulin M ( IgM ) paraprotein minimum IgM level &gt; 2 time upper limit normal , detectable lymphoplasmacytic ( LPL ) cell bone marrow , symptomatic WM . ECOG Performance Status ( PS ) 0 , 1 , 2 . The following laboratory value obtain prior registration : Absolute neutrophil count ( ANC ) great equal 1000/microL Platelet ( PLT ) count great equal 75,000/microL Total bilirubin less equal 1.5 x upper limit normal ( ULN ) ( total elevate check direct , normal , patient eligible ) Aspartate transaminase ( AST ) less equal 3 x ULN Creatinine less equal 1.5 x ULN Hemoglobin ( Hgb ) great equal 8.0 g/dL . Expected survival great 12 week . The ability provide inform consent . Male female patient reproductive potential must use approved contraceptive method , appropriate ( example , intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month discontinuation study treatment . Women childbearing potential must negative serum pregnancy test less equal 3 day prior study enrollment Prior allogeneic hematopoietic stem cell transplant . Are unable discontinue use nonEIAEDs , example carbamazepine , phenobarbital , phenytoin . Patients anticoagulant therapy monitor . Ongoing treatment therapeutic dos Coumadin prohibit . However , prophylactic , low dose ( less equal 2mg daily ) Coumadin DVT allow . In case , PT/INR closely monitor . Have ECG abnormality include baseline 12lead ECG QTc interval great 450 msec male great 470 msec female , QRS duration great 100 msec . Patients congenital longQTsyndrome family medical history exclude investigator 's discretion . Have uncontrolled infection . Have prior treatment BCNU 6 week , alkylating agent 4 week , cytotoxic chemotherapy agent 4 week prior registration trial . Have prior treatment biologic therapy less equal 12 week corticosteroids less equal 2 week prior registration trial . However , treatment le equal 10 mg prednisone chronic therapy allow . Have radiation therapy less equal 2 week prior treatment trial . Are pregnant breastfeeding . Are treated concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Are known HIV positive . Were previously treat enzastaurin . Patients unable swallow tablet . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Concurrent malignancy could complicate interpretation response safety evaluation . Nonmelanoma skin cancer carcinoma situ cervix exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>